Wyeth Indux
Executive Summary
Approval of long bone fracture healing indication for recombinant bone morphogenic protein expected by early 2002, American Home Products CEO Robert Essner tells analysts May 16. Indux (BMP-2) is in Phase III for three indications: long bone fracture, spinal fusion (with Medtronic/Sofamor Danek) and dental craniofacial use. In Phase III trials, standard care of a tibia fracture healed in 20 weeks, while standard care with Indux healed in 14 weeks with more complete bone fusion. Indux sales are expected to reach $500 mil. by 2004, Essner says
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth